Volume 7 Issue 8, Aug 2022

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 7 Issue 8, Aug 2022:
Letter
CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect
Mingyue Liu,Xu Wang,Xuexiang Du,Yan Zhang,Chunxia Ai,Siwen Hu-Lieskovan,Tianhong Li,Martin Devenport,Yang Liu  ORCID: orcid.org/0000-0002-9442-700X &…Pan Zheng